ArticleFrontiers in cellular and infection microbiology2021
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar.
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.Archives of virology · 2026Article
- Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.BMC infectious diseases · 2025Article
- Immune histories and natural infection protection during the omicron era.Communications medicine · 2025Article
- Article
- Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.Journal of medical microbiology · 2025Article
- Article
- Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design.American journal of epidemiology · 2024Article
- SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.Cell · 2024Article
- History of primary-series and booster vaccination and protection against Omicron reinfection.Science advances · 2023Article
- Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12-17 Years against COVID-19 Infection in Qatar.Vaccines · 2023Article
- Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.EBioMedicine · 2023Observational
- Sickness absenteeism among primary health care workers in Qatar before and during the COVID-19 pandemic.Journal of occupational medicine and toxicology (London, England) · 2023Article
- Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar.Journal of infection and public health · 2023Article
- Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual.Virus evolution · 2023Article
- Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection.Journal of travel medicine · 2022Article
- Mutational Patterns Observed in SARS-CoV-2 Genomes Sampled From Successive Epochs Delimited by Major Public Health Events in Ontario, Canada: Genomic Surveillance Study.JMIR bioinformatics and biotechnology · 2022Article
- Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.Human vaccines & immunotherapeutics · 2022Review
- Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Qatar, a country with a strong health system and a diverse population consisting mainly of expatriate residents, has experienced two large waves of COVID-19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome sequences from infected patients in Qatar between March-2020 and March-2021, representing 1.5% of all positive cases in this period. Despite the restrictions on international travel, the viruses sampled from the populace of Qatar mirrored nearly the entire global population's genomic diversity with nine predominant viral lineages that were sustained by local transmission chains and the emergence of mutations that are likely to have originated in Qatar. We reported an increased number of mutations and deletions in B.1.1.7 and B.1.351 lineages in a short period. These findings raise the imperative need to continue the ongoing genomic surveillance that has been an integral part of the national response to monitor the SARS-CoV-2 profile and re-emergence in Qatar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.